Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
Akt inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:ATCCode |
none (not approved)
|
| gptkbp:CASNumber |
1032350-13-2
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:hasMolecularFormula |
C25H21ClFN5O
|
| https://www.w3.org/2000/01/rdf-schema#label |
MK-2206
|
| gptkbp:intendedUse |
gptkb:cancer
|
| gptkbp:investigatedBy |
gptkb:non-small_cell_lung_cancer
gptkb:cancer colorectal cancer prostate cancer solid tumors hematologic malignancies |
| gptkbp:mechanismOfAction |
inhibits Akt (protein kinase B)
|
| gptkbp:molecularWeight |
463.92 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
gptkb:Akt_inhibitor_MK-2206
gptkb:MK2206 |
| gptkbp:target |
gptkb:Akt1
gptkb:Akt2 gptkb:Akt3 |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:bfsParent |
gptkb:AKT_(protein_kinase_B)
gptkb:AKT gptkb:phosphoinositide_3-kinase/AKT_pathway |
| gptkbp:bfsLayer |
6
|